bisantrene has been researched along with Hematologic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baruchel, A; Deméocq, F; Guillot, T; Leblanc, T; Lemerle, S; Leverger, G; Nelken, B; Schaison, G; Vannier, JP | 1 |
| Alberts, DS; Mackel, C; Meyskens, FL | 1 |
2 other study(ies) available for bisantrene and Hematologic Diseases
| Article | Year |
|---|---|
Treatment of relapsed or refractory acute leukemia in childhood with bisantrene combined with high dose aracytine.
Topics: Adolescent; Adult; Anthracenes; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Follow-Up Studies; Heart Diseases; Hematologic Diseases; Humans; Infant; Kidney Diseases; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1994 |
Phase II trial of bisantrene in patients with metastatic melanoma.
Topics: Adult; Aged; Anthracenes; Antibiotics, Antineoplastic; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis | 1986 |